🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 3 mab active

    1 trial

  2. Pembrolizumab (K)

    Merck KGaA, Darmstadt, Germany

    Breast Cancer

    phase 3 mab active

    1 trial

  3. Pembrolizumab/Vibostolimab

    Merck KGaA, Darmstadt, Germany

    Lung Neoplasms

    phase 3 mab completed

    1 trial

  4. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials

  5. Placebo

    Sanofi Pasteur

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  6. Placebo

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  7. Placebo Film-coated tablet, JNJ-42847922

    Janssen-Cilag International N.V.

    Major Depressive Disorder with Insomnia Symptoms

    phase 3 small molecule active

    1 trial

  8. Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  9. Placebo Ocrevus, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE , METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Ocrevus 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Dormutil N, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Primary progressive multiple sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  10. Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  11. Placebo for fezolinetant film-coated tablets 45 mg, fezolinetant

    Astellas Pharma GmbH

    Moderate to Severe Vasomotor Symptoms (VMS)

    phase 3 small molecule active

    1 trial

  12. Placebo pMDI to match budesonide/formoterol fumarate pMDI, PREDNISOLONE, Placebo MDI to match to Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, SALBUTAMOL, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension

    AstraZeneca AB

    Severe and inadequately controlled asthma

    phase 3 small molecule active

    1 trial

  13. Plegridy 125 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., Plegridy 63 micrograms+94 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5 ml solution for injection.

    Biogen

    Relapsing Remitting Multiple Sclerosis (RRMS)

    phase 3 small molecule active

    1 trial

  14. Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  15. Prevnar 13™

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  16. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  17. Recombinant human luteinizing hormone (r-hLH)

    Merck KGaA, Darmstadt, Germany

    Hypogonadism

    phase 3 small molecule completed

    1 trial

  18. Regorafenib (BAY73-4506)

    Bayer HealthCare AG

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  19. Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial

  20. SARCLISA 20mg/mL concentrate for solution for infusion., Iclusig 15 mg film-coated tablets, SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.

    Pari Pharma GmbH

    Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.

    phase 3 small molecule active

    1 trial

  21. SAU

    BRIGHT MINDS BIOSCIENCES INC.

    Signs and Symptoms

    phase 3 other completed

    1 trial

  22. SB11 (Proposed ranibizumab biosimilar)

    Samsung Bioepis NL B.V.

    Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  23. SPD489 Low-Dose

    Takeda

    Negative Symptoms of Schizophrenia

    phase 3 small molecule terminated

    1 trial

  24. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer

    phase 3 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources